Nuwellis, Inc. Announces New Purchase Agreement with Top 25 Largest Integrated Delivery Network
Nuwellis, Inc. (Nasdaq: NUWE) has recently announced a new purchase agreement with one of the top 25 largest integrated delivery networks (IDN) in the U.S. This agreement marks a significant milestone for Nuwellis, a medical technology company focused on transforming the lives of people with fluid overload.
The collaboration between Nuwellis and the IDN will expand access to Aquadex therapy, a cutting-edge ultrafiltration technology that helps improve patient care for individuals with fluid overload who are unresponsive to diuretics. This new network-wide agreement demonstrates a broader commitment to providing advanced medical solutions across the entire 50-hospital system within the IDN.
Nestor Jaramillo, Jr., President and Chief Executive Officer at Nuwellis, expressed excitement about the partnership, stating, “We are thrilled to be working with this leading hospital network to expand access to Aquadex therapy for a wider range of heart failure, critical care, and pediatric patients. Aquadex offers a safe and effective ultrafiltration option for patients with fluid overload, and this agreement demonstrates the dedication of this IDN to provide innovative treatment options for its patients.”
The announcement of this agreement comes on the heels of new data presented at the recent Technology and Heart Failure Therapeutics (THT) conference in early March. The data showcased a significant reduction in both 30-day hospitalizations and heart failure events for patients treated with Aquadex, further solidifying the benefits of this innovative therapy.
The Aquadex SmartFlow system, developed by Nuwellis, delivers clinically proven therapy for patients suffering from hypervolemia (fluid overload). It is indicated for use in adult and pediatric patients whose fluid overload is unresponsive to medical management, including diuretics. The system is designed to be used in both outpatient and inpatient clinical settings under physician prescription.
Nuwellis, Inc. is dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow system for ultrafiltration therapy and is headquartered in Minneapolis, with a subsidiary in Ireland.
This new partnership between Nuwellis and the IDN represents a significant step forward in providing advanced medical solutions for patients with fluid overload, showcasing the commitment of both organizations to improving patient care and outcomes.